Verastem plays the Kras card
For $3m Verastem adds to its pipeline another asset that a bigger company had given up on.
Triple meeting – Mirati avoids the worst-case scenario
Like AMG 510, MRTX849 yields partial responses in some lung and colorectal tumours, but investors could have expected better.
Triple meeting – clinical data, and competition, loom for Mirati
Mirati pulls a rabbit out of its hat, but the conference will serve up three new competitors too.
SITC 2019 preview – Nextcure’s time to shine
The biotech calendar’s next key conference gets under way in a month, and a presentation by Nextcure will be a focus for some investors.
Esmo 2019 – Kras springs a leak
Amgen’s AMG 510 disappoints Kras bulls, showing just two new partial responses, in colorectal and appendiceal tumours.
World Lung 2019 – Amgen tries to keep the pace in Kras chase
The latest cut of data from a trial of Amgen’s closely watched Kras inhibitor AMG 510 contains more encouraging signals in lung cancer, though some of the loftiest hopes…
Esmo 2019 preview – Parps on parade
Among small-molecule approaches Europe’s premier oncology conference gives star billing to three Parp inhibitors in ovarian cancer.
World Lung preview – Astra takes on Roche
Astra’s Caspian study is the star of next week’s World Lung conference, which has also given targeted approaches important supporting roles.
Redx sells another asset to keep the lights on
The UK biotech gets a big boost from the sale of a pan-Raf inhibitor to Jazz Pharmaceuticals, but Redx’s money worries are far from over.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.